News from shire plc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

12 Nov, 2016, 12:00 GMT Tolerability Data for Shire's CUVITRU Accepted for Oral Presentation at the American College Of Allergy, Asthma & Immunology Annual Meeting

Data reveals key findings on the tolerability of CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] for patients, regardless of treatment...


10 Nov, 2016, 12:00 GMT Shire's Investor Day Showcases Strength of Rare Disease Pipeline and Commercial Portfolio

Shire plc (LSE: SHP, NASDAQ: SHPG) today will host an Investor Day focused on its commercial portfolio and innovative R&D pipeline, including...


04 Nov, 2016, 15:00 GMT Broad Range of Research to be Presented at ASH 2016 Demonstrates Shire's Commitment to Addressing Unmet Needs for Patients with Rare Hematologic and Specialty Conditions

16 presentations to highlight innovation in hematology, oncology and genetic diseases Shire plc (LSE: SHP, NASDAQ: SHPG), the leading global...


04 Nov, 2016, 11:00 GMT Shire to Highlight Focus on Rare Disease Innovation at Investor Day

Company to discuss strength of its commercial portfolio and robust pipeline in rare diseases and specialized conditions Hematology and Immunology...


01 Nov, 2016, 12:37 GMT Shire Reports Q3 2016 Results with Record Revenues and Reiterates Full Year Non GAAP Guidance

Very strong U.S. launch for XIIDRA; marks outstanding entry into ophthalmics Baxalta integration progressing well with synergy initiatives ahead of...


18 Oct, 2016, 07:00 BST Shire Granted EU Marketing Authorization of Onivyde®, in Combination With 5-Fluorouracil (5-FU) and Leucovorin (LV),for the Treatment of Metastatic Adenocarcinoma of the Pancreas in Adult Patients Who Have Progressed Following Gemcitabine-Based Therapy

ONIVYDE, in combination with 5-fluorouracil (5-FU) and leucovorin (LV), is the first and only treatment approved for this patient population based on ...


17 Oct, 2016, 12:00 BST Shire Announces Update to Vyvanse® (lisdexamfetamine dimesylate) U.S. Labeling to Include New Longer-Term Maintenance of Efficacy Data in Adults with Moderate to Severe Binge Eating Disorder

Labeling Update Based on Maintenance of Efficacy Data from a 38-Week Phase 3 Study For U.S. Audiences Only - Shire plc (LSE: SHP, NASDAQ: SHPG)...


05 Oct, 2016, 23:07 BST Patent Trial and Appeal Board Upholds the Validity of LIALDA® Patent

Shire plc (LSE: SHP, NASDAQ: SHPG) announced today that the U.S. Patent & Trademark Office's Patent Trial and Appeal Board (PTAB) has issued their...


20 Sep, 2016, 00:28 BST Shire Prices Public Offering of Senior Notes

Shire plc (LSE: SHP, NASDAQ: SHPG) announced today that its wholly owned subsidiary, Shire Acquisitions Investments Ireland Designated Activity...


16 Sep, 2016, 21:49 BST District Court Issues Ruling in Hatch Waxman Case Regarding Shire's LIALDA®

Shire to consider appeal Shire plc (LSE: SHP, NASDAQ: SHPG) was informed today that the United States District Court for the District of Delaware has ...


14 Sep, 2016, 12:00 BST Shire Announces U.S. FDA Approval of CUVITRUTM [Immune Globulin Subcutaneous (Human), 20% Solution] Treatment for Primary Immunodeficiency

Approval follows positive data from clinical studies on efficacy and tolerability, as well as infusion time and number of injection sites Shire plc...


08 Sep, 2016, 14:07 BST Shire to Participate at Two Upcoming Investor Conferences

Shire plc (LSE: SHP, NASDAQ: SHPG) announces that Flemming Ornskov, MD, Chief Executive Officer, will present at the Morgan Stanley Global Healthcare ...


02 Sep, 2016, 23:30 BST Shire plc: U.S. Securities and Exchange Commission Filings

Shire plc (LSE: SHP, NASDAQ: SHPG) informs its shareholders that on September 2, 2016 it filed with the U.S. Securities and Exchange Commission...


29 Aug, 2016, 15:47 BST Shire's First Prescription Eye Drop, Xiidra™ (lifitegrast ophthalmic solution) 5% is Now Available in the U.S.

Xiidra is the only prescription eye drop approved by the U.S. FDA for the treatment of both signs and symptoms of dry eye disease Resources are...


25 Aug, 2016, 12:00 BST Shire and Jennifer Aniston Want to Inspire People to Show Their Eyes Some Love and Help Raise Awareness of Chronic Dry Eye

Jennifer Aniston Opens Up about Personal Experience with Dry Eye Symptoms, Which Have Been Reported by Nearly 30 Million Americans Jennifer Aniston...


02 Aug, 2016, 12:00 BST Shire Delivers Strong Q2 2016 Revenue Growth; Upgrades Outlook

Integration on track; operating cost synergy expectations increased Pipeline progression continues with FDA approval of XIIDRA for dry eye disease...


29 Jul, 2016, 12:00 BST Shire's SHP626 (Volixibat) Receives FDA Fast Track Designation for an Investigational Treatment for Adults Who Have Nonalcoholic Steatohepatitis (NASH) With Liver Fibrosis

Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation for...


25 Jul, 2016, 07:00 BST ONIVYDE® Receives Positive CHMP Opinion for Treatment of Patients with Metastatic Adenocarcinoma of the Pancreas Who Have Progressed Following Gemcitabine Based Therapy

The positive opinion is based on a pivotal Phase 3 study showing that ONIVYDE combined with chemotherapy significantly increased overall survival...


21 Jul, 2016, 12:00 BST Shire Launches Pediatric Indication for Immunodeficiency Treatment HyQvia in Europe

HyQvia (Human Normal Immunoglobulin 10% and Recombinant Human Hyaluronidase) is the only subcutaneous IG treatment for primary and certain secondary...


19 Jul, 2016, 12:00 BST Shire Reinforces Commitment in Hematology with Robust Data Presented at International Congress of the World Federation of Hemophilia

More than 40 presentations and sessions feature broad pipeline and proven factor replacement portfolio, with new innovation on outcomes, safety and...


12 Jul, 2016, 00:08 BST Regulatory Approval - FDA Approves Shire’s Xiidra™ (lifitegrast ophthalmic solution) 5% – The Only Treatment Indicated for the Signs and Symptoms of Dry Eye Disease

An estimated 16 million people in the U.S. are diagnosed with dry eye disease Xiidra is the first prescription eye drop FDA-approved to treat both...


07 Jul, 2016, 07:00 BST Shire Receives Extension of Market Authorization in Europe for Revestive▼ (Teduglutide) for the Treatment of Paediatric Patients with Short Bowel Syndrome (SBS)

This press release is intended for a global audience. First therapy indicated in the EU for use in patients aged one year and above with SBS, a rare...


30 Jun, 2016, 12:00 BST Shire Announces Top-Line Results for Phase 2 Trial of SHP607 in Extremely Premature Infants

Top-line SHP607 study results in extremely premature infants showed no impact on primary endpoint of reducing the severity of Retinopathy of...


14 Jun, 2016, 12:00 BST Shire to License PF-00547659 from Pfizer, Adding to Established and Leading Gastrointestinal Portfolio

PF-00547659 is being evaluated for inflammatory bowel disease and has completed Phase 2 trials Shire plc (LSE: SHP, NASDAQ: SHPG) today announced it...


13 Jun, 2016, 12:00 BST Shire Receives FDA Breakthrough Therapy Designation for SHP621 and SHP625, Investigational Products for Rare Gastrointestinal Conditions

Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for...